EUVIMEDEUVIMED entdecken
Crossref

Xenograft recipients and the right to withdraw from a clinical trial

Christopher Bobier iD, Daniel J Hurst iD, Daniel Rodger iD, Adam Omelianchuk iD

Bioethics · 2024

DOI: 10.1111/bioe.13262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioethics, 2024. Verfasst von Christopher Bobier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Theology and Philosophy, Associate Director, Hendrickson Institute for Ethical Leadership, St. Mary's University of Minnesota, Winona, …. Hauptthemen laut MEDLINE: Research Subjects, Tissue and Organ Procurement. Die Arbeit wurde bisher 14-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical xenotransplantation research using genetically engineered pigs has begun to show some promising results and could one day offer a scalable means of addressing organ shortage. While it is a fundamental tenet of ethical human subject research that participants have a right to withdraw from research once enrolled, several scholars have argued that the right to withdraw from xenotransplant research should be suspended because of the public health risks posed by xenozoonotic transmission. Here, we present a comprehensive critical evaluation of the claim that xenotransplant recipients should be required to waive their right to withdraw from lifelong biosurveillance. We conclude that if xenotransplantation requires participants to waive their right to withdraw, then clinical trials may not be justifiable, given the ethical and legal obstacles involved with doing so. Consequently, if clinical trials are permitted with a right to withdraw, then they may pose a significant public health risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research SubjectsTissue and Organ ProcurementAnimalsHumansHeterograftsSwineTransplantation, HeterologousClinical Trials as Topic

Stichwörter der Autor:innen

patient rightspublic healthxenotransplantationzoonosis

Autor:innen und Institutionen

  • Department of Theology and Philosophy, Associate Director, Hendrickson Institute for Ethical Leadership, St. Mary's University of Minnesota, Winona, Minnesota, USA.
  • Department of Family Medicine Rowan University School of Osteopathic Medicine Stratford, New Jersey, USA.
  • Institute of Health and Social Care, School of Allied and Community Health, London South Bank University, London, UK.
  • Department of Psychological Sciences, Birkbeck, University of London, London, UK.
  • Center for Medical Ethics and Health Policy at Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Christopher Bobier, Daniel J Hurst, Daniel Rodger, Adam Omelianchuk

Zitieren

APA

Bobier, C., Hurst, D. J., Rodger, D., & Omelianchuk, A. (2024). Xenograft recipients and the right to withdraw from a clinical trial. Bioethics. https://doi.org/10.1111/bioe.13262

Vancouver

Bobier C, Hurst DJ, Rodger D, Omelianchuk A. Xenograft recipients and the right to withdraw from a clinical trial. Bioethics. 2024. doi:10.1111/bioe.13262

BibTeX
@article{Bobier2024,
  author = {Bobier, Christopher and Hurst, Daniel J and Rodger, Daniel and Omelianchuk, Adam},
  title = {Xenograft recipients and the right to withdraw from a clinical trial},
  journal = {Bioethics},
  year = {2024},
  doi = {10.1111/bioe.13262}
}
Kostenlos starten →